| Cipla (EU), UK a wholly owned subsidiary of Cipla, hereinafter referred to as Cipla has announced a strategic collaboration with Kemwell Biopharma (through its subsidiary Kemwell Biopharma UK) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the United States. The primary goal of this joint venture is to develop and commercialise novel Cell therapy
products for major unmet medical needs in the United States, Japan, and EU regions.
Cipla (EU) will secure a 35.2% stake in the joint venture company. By capitalizing on Cipla's leadership in product development and commercialisation and aligning with Kemwell's expertise in biologics and Manipal's expertise in healthcare delivery, this strategic collaboration is aimed at expediting development, manufacturing, licensing, import and export of cutting-edge Cell therapy products to cater to patients globally. |